Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by research analysts at ValuEngine from a “strong-buy” rating to a “buy” rating in a research report issued on Tuesday, December 3rd, ValuEngine reports.
A number of other brokerages have also weighed in on TEVA. SunTrust Banks cut their target price on shares of Teva Pharmaceutical Industries to $7.00 and set a “hold” rating on the stock in a research report on Thursday, August 8th. UBS Group set a $8.00 price objective on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a research report on Friday, August 16th. Guggenheim assumed coverage on Teva Pharmaceutical Industries in a research report on Thursday, September 12th. They issued a “neutral” rating for the company. Wells Fargo & Co cut their price target on Teva Pharmaceutical Industries from $17.00 to $8.00 and set a “market perform” rating on the stock in a research note on Monday, September 30th. Finally, Raymond James lowered their price objective on Teva Pharmaceutical Industries from $22.00 to $15.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. Five analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have given a buy rating to the company’s stock. Teva Pharmaceutical Industries currently has a consensus rating of “Hold” and an average target price of $10.64.
Teva Pharmaceutical Industries stock opened at $10.12 on Tuesday. Teva Pharmaceutical Industries has a 52 week low of $6.07 and a 52 week high of $20.21. The company has a debt-to-equity ratio of 1.62, a quick ratio of 0.56 and a current ratio of 0.89. The stock has a fifty day moving average of $9.73 and a 200-day moving average of $8.29. The stock has a market capitalization of $10.89 billion, a P/E ratio of 3.61, a price-to-earnings-growth ratio of 1.07 and a beta of 1.83.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Thursday, November 7th. The company reported $0.56 EPS for the quarter, missing analysts’ consensus estimates of $0.58 by ($0.02). The company had revenue of $4.26 billion during the quarter, compared to the consensus estimate of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 15.41% and a negative net margin of 22.88%. On average, research analysts forecast that Teva Pharmaceutical Industries will post 2.26 earnings per share for the current year.
In other Teva Pharmaceutical Industries news, VP Hafrun Fridriksdottir sold 4,310 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $10.49, for a total transaction of $45,211.90. Following the completion of the transaction, the vice president now owns 24,883 shares in the company, valued at approximately $261,022.67. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.49% of the stock is currently owned by company insiders.
A number of institutional investors have recently modified their holdings of the business. AdvisorNet Financial Inc boosted its stake in Teva Pharmaceutical Industries by 71.3% during the third quarter. AdvisorNet Financial Inc now owns 3,665 shares of the company’s stock worth $25,000 after acquiring an additional 1,525 shares in the last quarter. First Interstate Bank bought a new stake in Teva Pharmaceutical Industries in the second quarter valued at $28,000. Motco acquired a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at about $28,000. Lindbrook Capital LLC raised its holdings in shares of Teva Pharmaceutical Industries by 76.6% during the third quarter. Lindbrook Capital LLC now owns 4,461 shares of the company’s stock valued at $31,000 after purchasing an additional 1,935 shares during the period. Finally, Pacer Advisors Inc. bought a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $32,000. Hedge funds and other institutional investors own 53.53% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Further Reading: Stock Portfolio Tracker
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Teva Pharmaceutical Industries Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com’s FREE daily email newsletter.
